NGeneBio Co., Ltd. (KOSDAQ:354200)

NGeneBio Statistics

Total Valuation

NGeneBio has a market cap or net worth of KRW 43.38 billion. The enterprise value is 70.58 billion.

Market Cap	43.38B
Enterprise Value	70.58B

Important Dates

The last earnings date was Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

NGeneBio has 26.12 million shares outstanding. The number of shares has increased by 60.90% in one year.

Current Share Class	26.12M
Shares Outstanding	26.12M
Shares Change (YoY)	+60.90%
Shares Change (QoQ)	+25.03%
Owned by Insiders (%)	7.21%
Owned by Institutions (%)	0.52%
Float	18.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.04
PB Ratio	1.92
P/TBV Ratio	2.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-12.73
EV / Sales	3.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.06

Financial Position

The company has a current ratio of 0.51, with a Debt / Equity ratio of 1.47.

Current Ratio	0.51
Quick Ratio	0.41
Debt / Equity	1.47
Debt / EBITDA	n/a
Debt / FCF	-0.97
Interest Coverage	-5.06

Financial Efficiency

Return on equity (ROE) is -16.64% and return on invested capital (ROIC) is -12.53%.

Return on Equity (ROE)	-16.64%
Return on Assets (ROA)	-9.83%
Return on Invested Capital (ROIC)	-12.53%
Return on Capital Employed (ROCE)	-34.01%
Weighted Average Cost of Capital (WACC)	8.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.40
Inventory Turnover	9.99

Taxes

Income Tax	-965.45M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.19% in the last 52 weeks. The beta is 1.31, so NGeneBio's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	+2.19%
50-Day Moving Average	2,018.84
200-Day Moving Average	1,812.17
Relative Strength Index (RSI)	36.38
Average Volume (20 Days)	318,861

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NGeneBio had revenue of KRW 21.24 billion and -5.54 billion in losses. Loss per share was -247.00.

Revenue	21.24B
Gross Profit	3.78B
Operating Income	-8.28B
Pretax Income	-4.32B
Net Income	-5.54B
EBITDA	-6.05B
EBIT	-8.28B
Loss Per Share	-247.00

Balance Sheet

The company has 5.68 billion in cash and 33.25 billion in debt, with a net cash position of -27.57 billion or -1,055.82 per share.

Cash & Cash Equivalents	5.68B
Total Debt	33.25B
Net Cash	-27.57B
Net Cash Per Share	-1,055.82
Equity (Book Value)	22.59B
Book Value Per Share	923.51
Working Capital	-23.63B

Cash Flow

In the last 12 months, operating cash flow was -8.48 billion and capital expenditures -25.85 billion, giving a free cash flow of -34.33 billion.

Operating Cash Flow	-8.48B
Capital Expenditures	-25.85B
Depreciation & Amortization	2.79B
Net Borrowing	-10.19B
Free Cash Flow	-34.33B
FCF Per Share	-1,314.69

Margins

Gross margin is 17.78%, with operating and profit margins of -38.97% and -26.09%.

Gross Margin	17.78%
Operating Margin	-38.97%
Pretax Margin	-20.33%
Profit Margin	-26.09%
EBITDA Margin	-28.48%
EBIT Margin	-38.97%
FCF Margin	n/a

Dividends & Yields

NGeneBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-60.90%
Shareholder Yield	-60.90%
Earnings Yield	-12.78%
FCF Yield	-79.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NGeneBio has an Altman Z-Score of -1.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.39
Piotroski F-Score	1